The new CEO Richard Ascroft brings more than 30 years of industry experience, including senior roles at Takeda ...

Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or ...

A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and ...

GS-1811, a potential first-in-class immunotherapy, is designed to target and deplete immunosuppressive Tregs in the tumor ...

The 2025 PRCA Spotlight Awards reinforced the central role of communications in building trust, shifting perspectives, and ...

The STAAR trial showed that a one-shot dose of ST-920 – now known as isaralgagene civaparvovec – was able to improve kidney ...

Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and ...

Scientists from Cincinnati Children's and colleagues based in Japan report achieving a major step forward in organoid ...

Saatchi & Saatchi Wellness announced Wednesday the appointments of three new leaders: Brendan Gallagher as president, Divya Dileep as chief creative officer and Beth Bour as the agency’s first-ever ...